enGenes Biotech Joins CPHI Worldwide 2026 in Milan
Vienna, Austria: – Join enGenes Biotech at CPHI Worldwide 2026, taking place from October 6 to 8 in Milan, Italy. The recombinant proteins and plasmid DNA specialist CDMO returns to the show to reconnect with the pharma industry and open new conversations around its E. coli production platforms.
enGenes Biotech is attending as a visitor this year rather than exhibiting on its own stand, and will be available for meetings throughout the show via the official CPHI networking app.
Built for Innovators Who Want Their Own E. coli Process
For companies developing a target molecule and weighing up whether to build an E. coli production process in-house or continue outsourcing it, CPHI Worldwide is one of the few places to have that conversation directly with the people who design these platforms. enGenes is using Milan to meet exactly this audience: innovators exploring E. coli-based manufacturing routes, and potential licensees and partners for its technology platforms and wider product portfolio.
Two Products, One Bioprocessing Toolkit
Among the topics on the agenda will be enGenes’ recombinant Protein A affinity ligands, produced using its E. coli platform and aimed at resin and membrane manufacturers seeking a European supply source, and -eXrase, the company’s recombinant endonuclease for nucleic acid removal in bioprocessing, built to improve scalability, foam control and downstream processing in industrial fermentation.
To read more, click to
open here https://www.pharmaceutical-networking.com/engenes-biotech-joins-cphi-worldwide-2026-in-milan/
Comments